I would like to present FUJIFILM Holdings’ financial results for the third quarter of the fiscal year ending March 2020.
1 Let me explain the main points of the third quarter of the fiscal year ending March 2020.
In the third quarter of the fiscal year ending March 2020, operating income decreased year-on-year by 4.2%. On a constant-currency basis, it increased by 2.9%. Net income attributable to FUJIFILM Holdings increased by 19.4% year-on-year, proceeding as planned for achieving the full-year ROE target of 8%.
The total revenue decreased due to a negative impact from the strong yen, the economic slowdown in China, and a decrease in demand after the consumption tax increase. While sales declined in the imaging and document business, healthcare expanded sales, driven by the medical systems, bio CDMO and regenerative medicine business. The operating income increased in healthcare and in document with improvements in profitability and a positive impact from structural reforms, though it decreased in the Imaging and Materials.
As a special note, last December, we announced the acquisition of the Hitachi’s Diagnostic Imaging-related Business. The completion of the acquisition is planned in July, subject to customary closing conditions and regulatory approvals. In January this year, we also announced that Fuji Xerox would change its corporate name to FUJIFILM Business Innovation Corp. on Apr. 1, 2021. As for the share buyback as of up to 50 billion yen, 18.8 billion yen was bought back as of the end of January.
2 Let’s move on to detailed performance information for the third quarter of the fiscal year ending March 2020.
Consolidated revenue totaled ¥1,728.4 billion, down 4.0% from the previous fiscal year. Operating income totaled ¥151.6 billion, down 4.2% from the previous fiscal year . Income before income taxes came to ¥166.5 billion, up 7.7% from the previous fiscal year due to such factors as the large gains on equity securities. Net income attributable to FUJIFILM Holdings totaled ¥120.7 billion, up 19.4% from the previous fiscal year.
3 Let’s move on to segment specific information.
The Imaging Solutions segment recorded revenue of ¥266.1 billion, down 12.4% year-on-year, due to such factors as decreased sales of photographic paper, instant photo systems and digital cameras. Operating income totaled ¥27.4 billion, down 42.8% from the previous fiscal year.
The Healthcare & Material Solutions segment recorded revenue of ¥741.2 billion, down 2.3% year-on-year, due to such factors as a declined demand for printing plates in the graphic systems business and continued production adjustments by LCD panel manufactures in the display material business. Operating income totaled ¥70.8 billion, up 1.1% from the previous fiscal year.
Within the Healthcare & Material Solutions segment, the healthcare business recorded revenue of ¥350.8 billion, up 2.3% year-on-year, due to a growth in the medical systems, bio CDMO and regenerative medicine business. Operating income totaled ¥20.0 billion, up 14.2% from the previous fiscal year.
The Document Solutions segment recorded revenue of ¥721.1 billion, down 2.3% year-on-year, mainly due to a decrease in export to the U.S. and Europe and decreased sales in China. Operating income totaled ¥80.5 billion, up 20.3% year-on-year with improved profitability and a positive impact from structural reforms.
4 First, I would like to present the results of our Imaging Solutions segment.
In the photo imaging business, revenue decreased due to such factors as declined sales of photographic paper and inventory adjustments of instant photo systems at some U.S. retailers in the first half of the fiscal year. In instant business, the sales was affected by a decrease in demand after the consumption tax increase in Japan. In the U.S. and Europe, though sell-in decreased to adjust market inventory in Q3, sell-through at main retailers increased during the year-end shopping season including Xmas compared to the previous year. We are aiming to expand sales mainly with attractive new products such as instax mini LiPlay and instax mini Link, a printer for smartphones.
In the electronic imaging business, revenue decreased from the previous fiscal year mainly due to a decline in the sales of entry-level mirrorless digital cameras under severe market conditions. The sales were solid for FUJIFILM GFX100, a mirrorless digital camera equipped with a large format sensor with the world’s highest 102 million pixels resolution, and FUJIFILM X-Pro3, a flagship model of the X series launched in November 2019. We are aiming to expand sales of new products such as FUJIFILM X-T200 to be launched this month.
In the optical device business, revenue decreased, reflecting a declined demand for various industrial use lenses such as on-vehicle lenses due to the economic slowdown in China. Fujifilm is enhancing a line-up of new products for business growth, such as FUJIFILM PROJECTOR Z5000, which combined optical technologies of FUJINON Lenses, and 4K Premier series, the world’s first 4K‐compatible broadcast lens with an AF function to be launched in March 2020.
In the Imaging Solutions segment, though revenue decreased compared to the previous fiscal year, and operating income also decreased compared to the previous fiscal year due to such factors as a decline in revenue and effect of exchange rate, we will enhance the sales further by providing products with competitive advantages utilizing our unique technologies, and by running effective promotions to achieve a performance target. 5 Next is our Healthcare & Material Solutions segment. In the healthcare business field, the medical systems business enjoyed brisk sales in such areas as medical IT, endoscopes and in-vitro diagnostics (IVD). In the bio CDMO business, the contract process development and manufacturing business for biopharmaceuticals increased by the consolidation of Biogen’s manufacturing subsidiary and enhancement of capacity. In the regenerative medicine business, revenue increased due to strong sales of culture media by FUJIFILM Irvine Scientific.
As for the highly functional materials business field, in the display materials business, although overall revenue decreased mainly due to production adjustments of LCD panels, the sales of new products related to OLED etc. showed steady growth. In the electronic materials business, though the sales of advanced peripheral materials related to photolithography were affected by market conditions, revenue remained at the same level as the previous fiscal year with solid sales of products such as color resist for image sensors. In the recording media business, sales increased for magnetic tapes for high volume data storage such as FUJIFILM LTO Ultrium8 Data Cartridge. In the graphic systems business, sales decreased due to a decline in the demand for printing plates. In inkjet business, sales decreased mainly in industrial inkjet printhead business effected by the economic slowdown in China.
In the Healthcare & Material Solutions segment, though overall revenue decreased, sales increased in the medical systems, bio CDMO and regenerative medicine business. Operating income increased primarily by improvements of profitability in healthcare.
6 Lastly, I would like to talk about the Document Solutions segment.
First, in the office products field within the office products and printers business, although the export to the U.S. and Europe and sales in China decreased, sales were strong for the ApeosPort-VII C series, flagship color multifunction devices that realize robust security environment in Japan.
In the production services business, overall sales volume increased. Strong sales continued in Japan and the export to the U.S. and Europe for the Iridesse™ Production Press, an on- demand color production printer.
In the solutions and services business, revenue increased due to expanded sales of one-stop services that support the design, introduction, maintenance and management of IT environments in offices in Japan. Fuji Xerox aims for further growth in the service field by continuously providing services that support customers in improvements of work efficiency and productivity.
Though revenue in the Document Solutions segment declined due to such factors as a decline in the export to the U.S. and Europe and weakened business confidence in China, operating income increased by such factors as improvements in profitability and a positive impact from structural reforms.
We will continue our efforts to expand growth areas such as the solutions and services business and the production services business, while enhancing profitability by promoting structural reforms.
7 Next, let’s look at our balance sheet.
Assets as of the end of December 2019 totaled ¥3,450.9 billion, increased by ¥36.2 billion from the end of March 2019.
Liabilities increased by ¥185.7 billion to ¥1,355.5 billion, mainly due to an increase in a corporate bond and long-term debt, and shareholders’ equity increased by ¥18.9 billion to total ¥2,055.9 billion.
The current ratio was 197.5%, decreased by 49.0 percentage points from the end of previous fiscal year. Our debt-equity ratio increased by 8.5 percentage points to 65.9%, and our shareholders’ equity ratio decreased by 0.1 percentage points to 59.6%.
8 Next, with regards to our cash-flow, net cash provided by operating activities totaled ¥162.4 billion, increased by ¥18.8 billion year-on-year due to a decrease in notes and accounts receivable and other factors. Net cash used in investing activities amounted to ¥202.4 billion, mainly due to such factors as acquisitions of businesses.
As a result, free cash flow without acquisitions of businesses and others was ¥69.6 billion.
9 Let me talk about the progress in structural reforms at Fuji Xerox.
10 One-time expenses including structural reform costs in the third quarter of the fiscal year ending March 2020 totaled ¥7.9 billion, while a positive impact from the structural reforms was ¥15.7 billion, proceeding as planned.
11 12 In Q3, our performance did not reach the consolidated financial plan due to the economic slowdown in China, decrease in demand after the consumption tax increase, and reaction against the rush demand before the consumption tax increase, which had more influence than expected. In Q4, we lowered our consolidated financial forecast from the previous forecast announced with the first half result, due to a compression of assets to strengthen the business structure of the graphic systems and inkjet business in anticipation of cooperation with the document business.
The forecast for the revenue has been revised to ¥2,370.0 billion, down ¥65.0 billion from the previous forecast.
The forecast for the operating income remains a record high, although it has been revised to ¥220.0 billion, down ¥20.0 billion from the previous forecast due to such factors as a compression of assets in the graphic systems and inkjet business and postponed lisencing-out in pharmaceutical and regenerative medicine business.
We revised the income before income taxes to ¥230.0 billion. Net income attributable to FUJIFILM Holdings has been revised upward to a record-high of ¥165.0 billion, up ¥3.0 billion from the previous forecast.
The ROE of 8%, originally targeted for the fiscal year ending March 2021, will be achieved one year ahead of the schedule.
Regarding the shareholder returns, share buyback of up to ¥50.0 billion will be completed within this fiscal year. The dividend for the fiscal year ending March 2020 is expected to be 95 yen par share, an increase of 15 yen from the previous fiscal year. 13 Earnings for FY2020/3 Q3 Appendix
14
FY2020/3 Q3 Appendix Analysis of Operating Income Change (Against FY2019/3 Q3 9Months)
170.0 (Billions of yen)
160.0 +0.5
-11.4
+15.1 -0.6 +3.0 150.0 -16.6
+1.7 +1.6 140.0 158.3
151.6
130.0
120.00 FY2019/3 Imaging Healthcare Document Structural Difference of FX Raw Others FY2020/3 Actual & reform structural material Actual Material positive reform price impact in expenses in Document Document
15 FY2020/3 Q3 Appendix Earnings for FY2020/3 Q3/9 Months
(Billions of yen)
Q3 9M
FY2019/3 FY2020/3 Change FY2019/3 FY2020/3 Change
Revenue 627.1 596.3 (30.8) 1,799.8 1,728.4 (71.4) 100.0% 100.0% -4.9% 100.0% 100.0% -4.0% 74.4 59.6 (14.8) 158.3 151.6 (6.7) Operating Income 11.9% 10.0% -19.9% 8.8% 8.8% -4.2%
Income before 55. 8 69. 0 13. 2 154. 6 166. 5 11. 9 Income Taxes 8.9% 11.6% +23.8% 8.6% 9.6% +7.7%
Net Income Attributable to 35.6 59.6 24.0 101.1 120.7 19.6 FUJIFILM Holdings 57%5.7% 10. 0% +67. 4% 56%5.6% 70%7.0% +19. 4%
Exchange US$/￥ ¥113 ¥109 (¥4) ¥111 ¥109 (¥2) Rates €/¥ ¥129 ¥120 (¥9) ¥129 ¥121 (¥8)
〈Other factors of change (Q3/9M YoY) 〉 Operating income --- Raw material prices: + ¥1.1 billion / + ¥3.0 billion
16
FY2020/3 Q3 Appendix Earnings for FY2020/3 Q3/9 Months
(Billions of yen) Q3 9M Revenue FY2019/3 FY2020/3Change FY2019/3 FY2020/3 Change
Imaging Solutions 127.9 112.0 (15.9) (-12.4%) 303.8 266.1 (37.7) (-12.4%) Healthcare 119.5 120.4 0.9 (+0.8%) 342.9 350.8 7.9 (+2.3%) Hlth&MtilHealthcare & Material Solutions 259.9 248.5 (11.4) (-4.4%) 758.9 741.2 (17.7) (-2.3%)
Document Solutions 239.3 235.8 (3.5) (-1.5%) 737.1 721.1 (16.0) (-2.2%) Total 627.1 596.3 (30.8) (-4.9%) 1,799.8 1,728.4 (71.4) (-4.0%) NtNote: After eli liimina tion o fitf intersegmen ttt transacti ons (Billions of yen) Q3 9M Operating Income [Operating Margin] FY2019/3 FY2020/3Change FY2019/3 FY2020/3 Change
Imaging Solutions 26.4 17.3(9.1)(-34.5%) 48.0 27.4 (20.6) (-42.8%) [20.6%] [15.4%] [15.7%] [10.3%] 15.0 8.9 17.4 20.0 Healthcare (6.1) (-41.3%)2.6 (+14.2%) [12.5%] [7.3%] [5.1%] [5.7%] Healthcare & Material 32.5 25.8 70.0 70.8 (6.7) (-20.7%) 0.8 (+1.1%) Solutions [12.5%] [10.4%] [9.2%] [9.6%] 23.6 25.6 66.9 80.5 Document Solutions 2.0 (+8.1%)13.6 (+20.3%) [9.9%] [10.9%] [9.0%] [11.2%] CtE&Corporate Expenses & (8.1) (9.1) (1.0) - (26.6) (27.1) (0.5) - Eliminations 74.4 59.6 158.3 151.6 Total (14.8) (-19.9%) (6.7) (-4.2%) [11.9%] [10.0%] [8.8%] [8.8%] 17 FY2020/3 Q3 Appendix Earnings for FY2020/3 Q3/9 Months Imaggging Solutions (Billions of yen) Q3 9M
Revenue FY2019/3 FY2020/3 Change FY2019/3 FY2020/3 Change Constant- Constant- currency basis currency basis Photo Imaging 90.8 83.0 (7.8) (-8.7%) (4.6) (-5.2%) 203.7 183.5 (20.2) (-10.0%) (13.8) (-6.8%) Electronic Imaging 26.6 20.7 (5.9) (-21.7%) (5.0) (-18.4%) 70.7 57.7 (13.0) (-18.3%) (10.4) (-14.6%) Optical Devices 10.5 8.3 (2.2) (-20.2%) (1.9) (-17.3%) 29.4 24.9 -4.5 (-15.2%) (3.8) (-12.8%)
Optical Device & Electronic Imaging 37.1 29.0 (8.1) (-21.3%) (6.9) (-18.1%) 100.1 82.6 (17.5) (-17.4%) (14.2) (-14.1%) Products
Total 127.9 112.0 (15.9) (-12.4%) (11.5) (-8.9%) 303.8 266.1 (37.7) (-12.4%) (28.0) (-9.2%)
Note: After elimination of intersegment transactions (Billions of yen) Q3 9M Operating Income [Operating Margin] FY2019/3 FY2020/3 Change Constant- FY2019/3 FY2020/3 Change Constant- currency basis currency basis 26.4 17.3 48.0 27.4 Imaggging Solutions (()9.1) (()-34.5%) (()7.6) (()-29.0%) (()20.6) (()-42.8%) (()16.6) (()-34.5%) [20.6%] [15.4%] [15.7%] [10.3%]
18
FY2020/3 Q3 Appendix Change in Quarterly Earnings by Segment
Imaging Solutions (Billions of yen)
Revenue Operating Income 127.9 125.0 112.0 30.0 100.0 90.8 26.4 Photo Imaggging (20.6%) 83.1 79.5 74.6 Electronic 75.0 Imaging Optical Device & 20.0 Electronic Imaging 83.0 17.3 Optical Products 53.8 (15.4%) Devices 50.0 46.9 53.6
Operating Income for Imaging Solutions 10.0 (Operati ng M argi in)
25.0 26.6 19.9 4.5 5.6 19.6 (6.0%) 20.7 3.1 17.4 (7.1%) 10.5 9.4 (3.7%) 8.1 8.5 8.3 0.0 0.0 18.Q3 18.Q4 19.Q1 19.Q2 19.Q3
19 FY2020/3 Q3 Appendix Earnings for FY2020/3 Q3/9 Months
Healthcare & Material Solutions (Billions of yen) Q3 9M Revenue FY2019/3 FY2020/3Change Constant-currency FY2019/3 FY2020/3 Change Constant-currency basis basis HlhHealthcare 119. 5 120. 4 090.9 (+0.8%) 373.7 (+3.2%) 342. 9 350. 8 797.9 (+2.3%) 15. 8 (+4.6%) Display Materials 26.3 21.5 (4.8) (-18.4%) (4.8) (-18.4%) 77.0 67.7 (9.3) (-12.1%) (9.3) (-12.1%) Industrial Products Electronic Materials 46.7 44.7 (2.0) (-4.3%) (0.6) (-1.4%) 134.4 129.9 (4.5) (-3.3%) (1.5) (-1.1%) Fine Chemical Highly Functional (-9.4%) (-7.5%) (-6.5%) (-5.1%) Materials 73.0 66.2 (6.8) (5.4) 211.4 197.6 (13.8) (10.8) Recording Media 9.2 9.2 0.0 (+0.1%) 0.4 (+4.2%) 27.2 32.4 5.2 (+19.0%) 6.0 (+21.9%) Graphic Systems/Inkjet 57.8 52.5 (5.3) (-9.4%) (3.6) (-6.4%) 176.4 159.5 (16.9) (-9.6%) (12.2) (-7.0%) Others 0.4 0.2 (()0.2) (()0.2) 1.0 0.9 (()0.1) (()0.1) Total 259.9 248.5 (11.4) (-4.4%) (5.1) (-2.0%) 758.9 741.2 (17.7) (-2.3%) (1.3) (-0.2%) Note: After elimination of intersegment transactions (Billions of yen) Q3 9M Operat ing Inco me [Operating Margin] FY2019/3 FY2020/3 Change Constant-currency FY2019/3 FY2020/3 Change Constant-currency basis basis 15.0 8.9 17.4 20.0 Healthcare (6.1) (-41.3%) (6.1) (-41.3%) 2.6 (+14.2%) 4.4 (+24.6%) [12.5%] [7.3%] [5.1%] [5.7%] Healthcare & Material 32. 5 25. 8 70. 0 70. 8 (6. 7) (-20.7%) (5. 8) (-17.9%) 080.8 (+1.1%) 464.6 (+6.5%) Solutions [12.5%] [10.4%] [9.2%] [9.6%]
20
FY2020/3 Q3 Appendix Change in Quarterly Earnings by Segment
Healthcare & Material Solutions (Billions of yen) Revenue Operating Income 280.1 265.1 259.9 248.5 250.0 Healthcare 32.5 227.6 (12.5%) 30.0 Display Materials
119.5 141.4 27.6 126.3 200.0 (9.9%) 25.8 Industrial Products 26.1 120.4 (10.4%) Electronic Materials 104.1 (9.9%) Fine Chemical 150.0 20.0 Recording Media 18.9 26.3 21.2 (8.3%) 25.4 21.5 20.8 Graphic Systems 100.0 Inkjet 45.4 46.7 44.0 41.2 44.7 10.0 Others 9.2 11.6 13.5 9.7 9.2 50.0 Operating Income for 57.8 60.3 51.5 55.5 52.5 Healthcare & Material Solutions 0.0 0.0 (Operating Margin) 18.Q3 18.Q4 19.Q1 19.Q2 19.Q3
21 FY2020/3 Q3 Appendix Earnings for FY2020/3 Q3/9 Months Document Solutions (Billions of yen)
Q3 9M Revenue FY2020/ FY2019/3 Change Constant-currency FY2019/3 FY2020/3 Change Constant-currency 3 bibasis bibasis
Office Printers 31.5 29.0 (2.5) (-8.1%) (1.9) (-5.9%) 94.2 89.1 (5.1) (-5.4%) (4.0) (-4.2%)
Office Products & Printers 139.3 133.4 (5.9) (-4.3%) (3.2) (-2.3%) 425.6 406.5 (19.1) (-4.5%) (12.9) (-3.0%)
Production Services 29.1 29.6 0.5 (+2.0%) 1.2 (+4.4%) 90.7 88.4 (2.3) (-2.5%) (0.4) (-0.4%)
Solutions & Services 60.0 65.2 5.2 (+8.8%) 6.4 (+10.8%) 184.3 201.8 17.5 (+9.5%) 21.1 (+11.5%)
Others 10.9 7.6 (3.3) (2.8) 36.5 24.4 (12.1) (11.1)
Total 239.3 235.8 (3.5) (-1.5%) 1.6 (+0.6%) 737.1 721.1 (16.0) (-2.2%) (3.3) (-0.5%)
Note: After elimination of intersegment transactions (Billions of yen) Q3 9M Operating Income FY2020/ FY2020/ [Operating Margin] FY2019/3 Change Constant-currency FY2019/3 Change Constant-currency 3 3 basis basis 23.6 25.6 66.9 80.5 Document Solutions 2.0 (+8.1%) 2.9 (+12.2%) 13.6 (+20.3%) 17.3 (+25.8%) [9.9%] [10.9%] [9.0%] [11.2%]
22
FY2020/3 Q3 Appendix Change in Quarterly Earnings by Segment
Document Solutions (Billions of yen) Revenue Operating Income
268.5 252.2 239.3 233.1 235.8
200.0 143.5 40.0 Office Products & Office Printers 139.4 33.2 139.3 133.7 133.4 Production Services 29.5 (13.2%) (11.0%) 25.6 Solutions & Services 23.6 (10.9%) 21.7 (9.9%) 32.6 100.0 (9.3%) 31.5 20.0 Others 29.1 27.3 29.6 Operating Income for Doc u ment Solu tions (Operating Margin) 76.9 60.0 62.5 74.1 65.2
0.0 0.0 18.Q3 18.Q4 19.Q1 19.Q2 19.Q3
23 FY2020/3 Q3 Appendix Revenue by Destination
(Billions of yen) FY2019/3 9M FY2020/3 9M Change Ratio (%) Ratio (%)
Japan 40.3% 724.7 42.3% 730.5 5.8 (+0.8%)
The Americas 19. 6% 353. 7 18. 6% 322. 9 (30. 8) ((8-87%).7%)
Europe 13.2% 237.1 13.1% 225.9 (11.2) (-4.7%)
China 12.6% 226.0 12.1% 209.5 (16.5) (-7.3%)
Asia and others 26.9% 484.3 26.0% 449.1 (35.2) (-7.3%)
Overseas 59.7% 1,075.1 57.7% 997.9 (77.2) (-7.2%)
Conso lidtdttllidated total 100. 0% 179981,799.8 100. 0% 172841,728.4 (71. 4) (40%)(-4.0%)
24
FY2020/3 Q3 Appendix Capital Expenditure, Depreciation & Amortization
Capital Expenditure (9M) (Billions of yen) 58.7 Q3 9 months Full year 8.7 46.3 46.5 FY FY FY FY FY FY FY FY FY2020/3 2018/3 2019/3 2020/3 2018/3 2019/3 2020/3 2018/3 2019/3 (forecast) 6.2 6.7 Imaging 2.4 1.6 2.9 6.2 6.7 8.7 9.4 10.6 Healthcare & Material 10. 2 11. 2 14. 6 27. 3 30. 0 41. 2 42. 7 50. 5 41.2 27.3 30.0 Document 3.7 3.2 3.1 11.9 7.9 7.7 13.8 11.7 Corporate 0.4 1.5 0.3 0.9 1.9 1.1 1.6 2.6 Capex * 16.7 17.5 20.9 46.3 46.5 58.7 67.5 75.4 90.0 11.9 797.9 7.7 Imaging 3.3 3.6 3.8 9.8 10.6 10.8 13.3 14.1 FY FY FY Healthcare & Material 14.6 15.9 16.9 42.8 45.6 47.4 57.5 63.1 2018/3 2019/3 2020/3 Depreciation & Amortization (9M) Document 15.3 12.2 10.0 40.9 37.7 31.8 54.7 50.1 95.3 95.6 91.8 Corporate 0.5 0.7 0.6 1.8 1.7 1.8 2.1 2.6 9.8 10.6 10.8 Depreciation& Amortization 33.7 32.4 31.3 95.3 95.6 91.8 127.6 129.9 128.0
Depreciation * 42.8 45.6 16.6 17.5 17.8 49.4 50.9 51.2 66.5 70.9 47.4 Nt Imaging Healthcare & Material *Note : Figures do not include amounts for rental equipment handled by the Document Solutions segment and others. 40.9 37.7 Document 31.8 Corporate
FY FY FY 2018/3 2019/3 2020/3
25 FY2020/3 Q3 Appendix R&D Expenses, SG&A Expenses
(Billions o f yen )
R&D Expenses (9M) Q3 9 months Full Year FY2020/3 FY2019/3 FY2020/3 FY2019/3 FY2020/3 FY2019/3 115.8 118.0 (forecast) 7.2 7.9 Imaging 2.3 2.4 7.2 7.9 9.9 Healthcare & 15.9 16.6 50.9 51.4 69.8 Material 50.9 51.4 Document 12.0 12.6 39.2 38.4 51.2 Corporate 6.1 6.7 18.5 20.3 25.2 R&D Expenses 36.3 38.3 115.8 118.0 156.1 155.0 39.2 38.4
18.5 20.3 SG&A Expenses 156.8 151.6 480.3 453.5 631.6
Imaging Healthcare & Material Document Corporate
26
FY2020/3 Q3 Appendix
Exchange Rates, Raw Material Prices, and Number of Employees
Exchange Rates (yen) FY2019/3 FY2020/3 Full year Q1 Q2 Q3 9M Q4 Full year Q1 Q2 Q3 9M (forecast) US$/¥ 109 111 113 111 110 111 110 107 109 109 109 €/¥ 130 130 129 129 125 128 123 119 120 121 121
Raw Material Prices (Average) (¥1,000/kg) FY2019/3 FY2020/3 Full year Q1 Q2 Q3 9M Q4 Full year Q1 Q2 Q3 9M (forecast) Silver 58 54 53 55 55 55 53 57 60 57 59
Number of Employees 2018.Dec 2019.Mar 2019.Jun 2019.Sep 2019.Dec Consolidated Total 74,425 72,332 72,358 72,842 73,092
27 Forecast for FY2020/3 Consolidated Financial Forecast for FY2020/3 by Segment (as of Feb. 06, 2020)
(Billions of yen) Change from FY2020/3 Change from Revenue FY2019/3 FY2020/3 previous (if(previous forecast) previous year forecast
Imaging Solutions 386.9 370.0 350.0 (36.9) (-9.5%) (20.0) Healthcare 484.3 520.0 505.0 20.7 (+4.3%) (15.0) Material 554.7 545.0 530.0 (24.7) (-4.5%) (15.0) Healthcare & Material (-0.4%) Solutions 1,039.0 1,065.0 1,035.0 (4.0) (30.0) Document Solutions 1,005.6 1,000.0 985.0 (()20.6) (-2.0%) (()15.0) Total 2,431.5 2,435.0 2,370.0 (61.5) (-2.5%) (65.0) Note: After elimination of intersegment transactions. Change from FY2020/3 Change from Oppgerating Income FY2019/3 FY2020/3 previous (prev ious forecast) previous year forecast Imaging Solutions 51.1 40.0 35.0 (16.1) (-31.5%) (5.0) Healthcare 33.348.043.09.7(+29.1%) (5.0) Material 64.3 71.0 61.0 (3.3) (-5.1%) (10.0) Healthcare & Material (+6.6%) Solutions 97.6 119.0 104.0 6.4 (15.0) Document Solutions 96.4 119.0 119.0 22.6 (+23.4%) 0.0 Corporate Expenses & Eliminations (35.3) (38.0) (38.0) (2.7) - 0.0 Total 209.8 240.0 220.0 10.2 (+4.8%) (20.0)
28
Forecast for FY2020/3 Shareholder Returns ■Dividend Dividend for FY2020/3 is planned at ¥95 per share , increased by ¥15 from the previous fiscal year. The dividend increase is planned for 10 consecutive years.
¥95
¥80 ¥75 ¥70 ¥65 ¥60
¥50
¥40 ¥35 ¥30 ¥25
FY'10/3 FY'11/3 FY'12/3 FY'13/3 FY'14/3 FY'15/3 FY'16/3 FY'17/3 FY'18/3 FY'19/3 FY'20/3 (forecast)
29 FY2020/3 Q3 Appendix
Pipeline (as of Feb. 06, 2020)
Development Therapeutic category Formulation Region Development stage code
Japan Approved Anti-influenza drug Oral T-705 U.S.A. PⅢ Severe fever with thrombocytopenia syndrome virus drug Oral Japan PⅢ
T-3811 Quinolone synthetic antibacterial drug Oral China Approved
U.S.A. PⅡ Alzheimer's disease drug Japan PⅡ T-817MA Oral Europe PⅡ Functional recovery after stroke （Promoting the effect of rehabilitation） Japan PⅡ Submitted an application for permission T-4288 New fluoroketolide antibacterial drug Oral Japan
Japan PⅠ FF-10501 Myelodysplastic syndrome drug Oral U.S.A. PⅡ FF-10502 Advanced/recurrent solid cancer drug Injection U.S.A. PⅡ
FF-21101 Bio Advanced/recurrent solid cancer drug (Armed antibody) Injection U.S.A. PⅡ
F-1311 Diagnostic drug for prostate cancer (Radiopharmaceuticals) Injection Japan PⅡ
FF-10101 Acute Myeloid Leukemia (AML) drug Oral U.S.A. PⅠ
F-1515 Anti-tumor (neuroendocrine tumors) drug (Radiopharmaceuticals) injection Japan PⅠ/Ⅱ
FF-10832 Advanced solid cancer drug (Gemcitabine liposome） Injection U.S.A. PⅠ
FF-10850 Advanced solid cancer drug (Topotecan liposome） Injection U.S.A. PⅠ
F-1614 Anti-tumor (pheochromocytoma) drug (Radiopharmaceuticals) Injection Japan PⅡ T-2307 was licensed-out to Appili Therapeutics in November 2019. 30
FY2020/3 Q3 Appendix Appendix
FUJIFILM Holdings － Investor Relations https://ir.fujifilm.com/en/investors.html FUJIFILM Holdings Integrated Report 2019 https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html IR Events Materials https://ir.fujifilm.com/en/investors/ir-materials/presentations.html ・ Business presentation materials -Jan. 2019 Business Presentation for Pharmaceuticals/Bio CDMO/Regenerative Medicine Business -Feb. 2019 ESG Briefing -Nov. 2019 Bio CDMO Business Briefing
Business Activities of FUJIFILM Group https://ir.fujifilm.com/en/investors/value/business.html Global Branding Campaign: NEVER STOP 31 https://brand.fujifilm.com/neverstop/en/ At F ujifil m, we are conti nuousl y i nnovati ng — creating new technologies, products and services that inspire and excite people everywhere. Our goal is to empower the potential and expand the horizons of tomorrow’s businesses and lifestyles.
Corporate Communication Office, Corporate Planning Div. https://holdings.fujifilm.com/en